BioCell Collagen Clinical Evidence
Unpublished Study by Miami Research Associates
Sheldon, E. A randomized double blind clinical pilot trial evaluating the safety and efficacy of hydrolyzed collagen type II (BioCell Collagen II®) in adults with osteoarthritis. 2003; Apr 25.
How does BioCell Collagen II compare with placebo as a way to increase joint mobility in subjects with osteoarthritis?
One of the defining features of arthritis is a loss of joint mobility. BioCell Collagen II is a
low-molecular- weight dietary supplement consisting of hydrolyzed chicken sternal cartilage extract that is similar in composition to human articular cartilage.
Can it help?
Human clinical intervention trial
Subjects received either BioCell Collagen II or placebo for 8 weeks. They were evaluated for 6 efficacy endpoints — perceived pain, stiffness, activities of daily living, total WOMAC score, quality of life, and quality of sleep — at base line and at weeks 4 and 8.
16 subjects with osteoarthritis of either the hands or knees, with associated joint mobility restriction
2 grams/day for 8 weeks
The BioCell Collagen II group showed a significant improvement over time in all WOMAC (pain, stiffness, activities of daily life) and quality-of life scores, whereas no significant changes in efficacy outcome were seen in the placebo group.
According to the lead researcher, daily intake of BioCell Collagen II led to “meaningful improvements that were significantly superior to the group receiving placebo supplements.” He added: “This preliminary study suggests that BioCell Collagen II has a promise in the management of chronic joint symptoms.”
Journal of Agriculture and Food Chemistry
Schauss, A.G., et al. Effect of the novel low molecular weight hydrolyzed chicken sternal cartilage extract, BioCell Collagen, on improving osteoarthritis-related symptoms: A randomized, double-blind, placebo-controlled trial. 2012 Apr 25; 60(16):4096–4101.
Is BioCell Collagen (BCC) a tolerable and efficacious treatment for osteoarthritis?
Previously, a preliminary study suggested that BioCell Collagen had promise in the management of chronic joint symptoms. This trial was undertaken to see if the results would remain consistent with a larger sample size.
Human clinical intervention trial
Randomized, double-blind, placebo-controlled Subjects received either BioCell Collagen or placebo for 8 weeks. Outcome measures included pain levels (as ranked by Physician Global Assessment scores), visual analogue scale for pain, and WOMAC scores, all assessed at baseline and on days 35 and 70.
80 subjects with physician-verified evidence of progressive osteoarthritis of the hip or knee, with joint pain present for 3 months or longer and pain levels ranked 4 or higher by Physician Global Assessment scores
2 grams/day for 70 days
Compared with the placebo group, the BioCell Collagen group experienced a significant improvement in physical activities on days 35 and 70.
“BCC was well tolerated and found to be effective in managing OA-associated symptoms over the study period, thereby improving subject’s activities of daily living. BCC can be considered a potential complement to current OA therapies.”
Current Medical Research and Opinion
Bello, A., et al. Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature. 2006; (22):2221–2232.
Is collagen hydrolysate an effective treatment for osteoarthritis?
Numerous studies have been conducted on collagen hydrolysate. What is the sum total of the evidence supporting its use in the treatment of osteoarthritis?
The authors note that, according to published research (4 open-label and 3 double-blind studies were identified and reviewed), orally administered collagen hydrolysate:
- Is absorbed intestinally and accumulates in cartilage
- Increases the synthesis of extracellular matrix molecules by chondrocytes (cartilage cells)
- Provides improvements in some measures of pain and function in people with arthritic conditions
“A growing body of evidence provides a rationale for the use of collagen hydrolysate for subjects with OA.”
Mechanism of Action
BioCell Collagen is composed of three key constituents: collagen peptides (60%), hyaluronic acid (10%), and chondroitin sulfate (30%). It is thought to exert its joint-supporting action in multiple ways. First, it may support the cartilage matrix by providing building blocks of structural proteins and glycosaminoglycans critical for the health of connective tissues. Second, preliminary research indicates it may directly stimulate cartilage cells to produce type II collagen and prostaglandins. And third, it may promote joint cushioning by replenishing hyaluronic acid, the primary lubricating agent in synovial fluid.